Basilea Initiates First Human Trial for Novel Antibiotic BAL2420 Targeting Drug-Resistant Gram-Negative Bacteria

Event summary

  • Basilea dosed the first healthy volunteer in a phase 1 study of BAL2420, a novel antibiotic targeting LptA in Gram-negative bacteria.
  • BAL2420 is designed to combat multidrug-resistant strains of Enterobacteriaceae, including E. coli and K. pneumoniae.
  • The study is a single-center, randomized, dose-escalation, double-blind, and placebo-controlled trial assessing intravenous administration.
  • CARB-X has supported BAL2420’s development since 2020, with funding from the US Department of Health and Human Services and other international sources.

The big picture

Basilea’s phase 1 trial of BAL2420 comes as global health agencies warn of widespread antibiotic resistance, particularly in Gram-negative bacteria. The study’s success could validate a new class of antibiotics, addressing a critical gap in treating multidrug-resistant infections. CARB-X’s involvement underscores the strategic importance of this development in the broader fight against antimicrobial resistance.

What we're watching

Clinical Efficacy
How BAL2420’s novel mechanism of action will perform against high-priority pathogens like carbapenem-resistant Enterobacteriaceae.
Regulatory Pathway
Whether the phase 1 data will support accelerated approval pathways given the urgent need for new antibiotics.
Market Differentiation
The pace at which Basilea can position BAL2420 as a competitive alternative to last-resort antibiotics like colistin.